GEMOFILIYA: PATOGENEZI, KLINIK-LABORATOR DIAGNOSTIKASI VA ZAMONAVIY DAVOLASH YONDASHUVLARI

Authors
  • Meliyev Behruzbek Samariddin o‘g‘li

    Toshkent davlat tibbiyot universiteti Chirchiq filiali, talaba

    Author

  • Maxmudova Marhabo Maxammadjanova

    Toshkent davlat tibbiyot universiteti Chirchiq filiali, ilmiy rahbar, falsafa doktori (PhD), dotsent

    Author

Keywords:
Array
Abstract

Dolzarbligi. Gemofiliya VIII (gemofiliya A) yoki IX (gemofiliya B) ivish omili yetishmovchiligi tufayli rivojlanadigan, X-xromosomaga bog‘liq retsessiv irsiy qon ketish kasalligidir. So‘nggi yillarda davolash omil o‘rnini bosuvchi preparatlardan uzoq ta’sir qiluvchi omillar, no-omilli vositalar va gen terapiyasigacha kengaydi, shu sababli yangi dalillarni tizimlashtirish zarur. Maqsad. Gemofiliyaning genetik asoslari, patogenezi, klinik-laborator diagnostikasi va zamonaviy davolash yondashuvlari bo‘yicha xalqaro adabiyotlarni tahlil qilish. Material va usullar. Narrativ adabiyotlar sharhi bajarildi. 2016–2026-yillarda e’lon qilingan xalqaro klinik qo‘llanmalar, III faza klinik tadqiqotlari va sharhlar tahlil qilindi; inhibitorlar bo‘yicha asosiy tadqiqot (2013-yil) kiritildi. Natijalar. Tug‘ilish paytida gemofiliya A 100 000 erkak chaqaloqqa 24,6 holatda, gemofiliya B esa 5,0 holatda uchraydi. Tashxis faollashtirilgan qisman tromboplastin vaqti uzayganda VIII va IX omillar faolligini aniqlashga, inhibitorlar esa Betesda usulida baholashga asoslanadi. Og‘ir va o‘rtacha og‘ir shakllarda profilaktik davolash epizodik davolashdan afzal ko‘riladi. Emicizumab profilaktikasi inhibitorsiz bemorlarda yillik qon ketishlar sonini 96–97 % ga, inhibitorli bemorlarda 79–87 % ga kamaytirdi; efanesoctocog alfa haftada bir marta qo‘llanganda yillik qon ketishlarning o‘rtacha soni 0,71 ni tashkil etdi. Bir martalik gen terapiyasi tanlangan bemorlarda qon ketishlar sonini sezilarli kamaytirdi, ammo jigar fermentlarining oshishi, uzoq muddatli natijalar va yuqori narx masalalari ochiq qolmoqda. Bevosita taqqoslovchi tadqiqotlar mavjud emas. Xulosa. Zamonaviy boshqaruvda individual tanlangan profilaktika, laborator monitoring, inhibitorlarni nazorat qilish va gemofiliya bo‘yicha ixtisoslashgan markazlarda kompleks yordam asosiy o‘rin tutadi. Yangi preparatlarni tanlashda dalillarning cheklovlari va mahalliy imkoniyatlarni hisobga olish zarur.

References

Srivastava A., Santagostino E., Dougall A., Kitchen S., Sutherland M., Pipe S.W. et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1-158. https://doi.org/10.1111/hae.14046

Iorio A., Stonebraker J.S., Chambost H., Makris M., Coffin D., Herr C. et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540-546. https://doi.org/10.7326/M19-1208

Berntorp E., Fischer K., Hart D.P., Mancuso M.E., Stephensen D., Shapiro A.D. et al. Haemophilia. Nat Rev Dis Primers. 2021;7(1):45. https://doi.org/10.1038/s41572-021-00278-x

Rezende S.M., Neumann I., Angchaisuksiri P., Awodu O., Boban A., Cuker A. et al. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the GRADE methodology. J Thromb Haemost. 2024;22(9):2629-2652. https://doi.org/10.1016/j.jtha.2024.05.026

van Galen K.P.M., d’Oiron R., James P., Abdul-Kadir R., Kouides P.A., Kulkarni R. et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH. J Thromb Haemost. 2021;19(8):1883-1887. https://doi.org/10.1111/jth.15397

Pulles A.E., Mastbergen S.C., Schutgens R.E.G., Lafeber F.P.J.G., van Vulpen L.F.D. Pathophysiology of hemophilic arthropathy and potential targets for therapy. Pharmacol Res. 2017;115:192-199. https://doi.org/10.1016/j.phrs.2016.11.032

Peyvandi F., Oldenburg J., Friedman K.D. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14(2):248-261. https://doi.org/10.1111/jth.13215

von Drygalski A., Chowdary P., Kulkarni R., Susen S., Konkle B.A., Oldenburg J. et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388(4):310-318. https://doi.org/10.1056/NEJMoa2209226

Oldenburg J., Mahlangu J.N., Kim B., Schmitt C., Callaghan M.U., Young G. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818. https://doi.org/10.1056/NEJMoa1703068

Mahlangu J., Oldenburg J., Paz-Priel I., Negrier C., Niggli M., Mancuso M.E. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822. https://doi.org/10.1056/NEJMoa1803550

Matsushita T., Shapiro A., Abraham A., Angchaisuksiri P., Castaman G., Cepo K. et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389(9):783-794. https://doi.org/10.1056/NEJMoa2216455

Ozelo M.C., Mahlangu J., Pasi K.J., Giermasz A., Leavitt A.D., Laffan M. et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013-1025. https://doi.org/10.1056/NEJMoa2113708

Pipe S.W., Leebeek F.W.G., Recht M., Key N.S., Castaman G., Miesbach W. et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706-718. https://doi.org/10.1056/NEJMoa2211644

Gouw S.C., van der Bom J.G., Ljung R., Escuriola C., Cid A.R., Claeyssens-Donadel S. et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231-239. https://doi.org/10.1056/NEJMoa1208024

Ní Áinle F., DiMichele D., Falck-Ytter Y., Smit C., De Paula E.V., Seth T. et al. ISTH clinical practice guideline for treatment of congenital hemophilia A and B based on the GRADE methodology: considerations for practice management and implementation. J Thromb Haemost. 2024;22(9):2404-2409. https://doi.org/10.1016/j.jtha.2024.06.002

Cover Image
Downloads
Published
2026-10-19
Section
Articles